Discover 191 paid clinical trials in North Dakota. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
North Dakota offers many paid research opportunities statewide, giving healthy volunteers and individuals with specific health needs access to a wide range of clinical studies. Key cities like Fargo, Bismarck, and Grand Forks are home to research centers actively recruiting participants, offering access to the latest treatments and medical advancements.
Filter
1
Filter results
Results: 191
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
for
Cancer
Location: Fairhaven MA, Norwich CT, York PA, East Syracuse NY,
Sponsor: Tempus AI
Sex: All
Age: 18 - 70+
Code: NCT06207032
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)
for
Carcinoma, Non-Small-Cell Lung
Location: Lebanon NH, Philadelphia PA, Columbus OH, Houston TX,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT04165070
Phase 1, Phase 2, Recruiting
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
for
Non-small Cell Lung Cancer
Location: Sydney, Saint John, Scarborough ME, West Haven CT,
Sponsor: AstraZeneca
Sex: All
Age: 18+
Code: NCT06692738
Phase 3, Recruiting
Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)
for
Myelodysplastic Syndrome
Location: Boston MA, Lebanon NH, Stony Brook NY, Long Branch NJ,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06577441
Phase 2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Location: Halifax, Scarborough ME, Boston MA, Providence RI,
Sponsor: Children's Oncology Group
Sex: All
Age: 3 - 29
Code: NCT06368817
Phase 2, Recruiting
Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age
for
Amblyopia
Location: Beverly MA, Boston MA, New Haven CT, New York NY,
Sponsor: Jaeb Center for Health Research
Sex: All
Age: 4 - 7
Code: NCT06380517
Phase 3, Recruiting
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
for
Head and Neck Squamous Cell Carcinoma
Location: Boston MA, New York NY, Philadelphia PA, Baltimore MD,
Sponsor: Tempus AI
Sex: All
Age: 18+
Code: NCT06163534
Recruiting
Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
for
Age-related Wet Macular Degeneration
Location: Manchester CT, Philadelphia PA, Deerfield Beach FL,
Sponsor: Caregen Co. Ltd.
Sex: All
Age: 50+
Code: NCT06132035
Phase 1, Recruiting
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
for
Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8,
Location: Augusta ME, Scarborough ME, South Portland ME,
Sponsor: National Cancer Institute (NCI)
Sex: All
Age: 18+
Code: NCT06498635
Phase 3, Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
for
Triple-Negative Breast Cancer
Location: Halifax, Moncton, Rimouski, Farmington CT, New Haven CT,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06393374
Phase 3, Recruiting
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
for
Metastatic Non Small Cell Lung Cancer
Location: New York NY, Montreal, Camden NJ, Richmond VA,
Sponsor: Iovance Biotherapeutics, Inc.
Sex: All
Age: 18 - 70
Code: NCT04614103
Phase 2, Recruiting
Contoura With Phorcides Compared to Wavefront Optimized LASIK
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
for
HPV-unrelated Head and Neck Squamous Cell Carcinoma
Location: St Louis MO, Fargo ND, Sioux Falls SD
Sponsor: Washington University School of Medicine
Sex: All
Age: 18+
Code: NCT04966481
Phase 3, Recruiting
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)